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Abstract 
Disease progression in alcoholic and non-alcoholic fatty liver disease shows 
sex-specific differences and is influenced by mechanisms linked to oxidative stress. 
Acetaldehyde plays a critical pathogenic role but its effects are mitigated by the 
activity of aldehyde dehydrogenases. Aldehyde dehydrogenase 1b1 (Aldh1b1) is the 
aldehyde dehydrogenase isoform with the second highest affinity for acetaldehyde 
after Aldh2, and is highly expressed in the intestine and liver. We examined sex 
differences and the effect of Aldh1b1 depletion in a murine model of chronic alcohol-
induced liver disease. Male and female wild-type and Aldh1b1-depleted mice 
received either ethanol (10-20% v/v) in drinking water or water alone for one year, 
and livers were examined histopathologically, histochemically and by 
immunohistochemistry. A significant increase in hepatic steatosis was observed in 
female mice after one year of ethanol consumption, and expression of ethanol-
metabolising enzymes and up-regulation by ethanol was also sex-dependent. 
Ethanol-induced hyperproliferation of hepatocytes was observed in female and male 
wild-type mice, and Aldh1b1 depletion enhanced this effect in males. Further, one 
ethanol-treated, Aldh1b1-depleted male developed a steatohepatitic hepatocellular 
carcinoma. These sex-specific differences in susceptibility to hepatic steatosis and 
disease progression may be related to differences in expression of ethanol-
metabolising enzymes, informing the clinically significant differences. Aldh1b1 plays 
a role in protection from ethanol-induced hepatocellular hyperproliferation and may 
protect from tumour development. 
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Introduction 
Hepatic steatosis has a high prevalence in the population. Steatosis accompanied by 
characteristic histological inflammation and hepatocellular ballooning represents 
steatohepatitis, with associated fibrosis that can progress to cirrhosis carrying an 
increased risk of hepatocellular carcinoma (HCC)(Bellentani et al., 2004). Both 
alcohol consumption and obesity are recognised as major risk factors for steatotic 
liver disease(Bellentani et al., 1994, 2004; Völzke, 2012), alcoholic liver disease 
(ALD) and non-alcoholic fatty liver disease (NAFLD), respectively. Disease 
mechanisms and risk factor interactions for ALD and NAFLD have not been fully 
clarified, but their influence on disease progression and HCC development is 
synergistic(Hart et al., 2010; Loomba et al., 2013). Females are believed to be more 
susceptible to alcohol-induced liver disease, although the reasons are not completely 
understood. Putative mechanisms include oestrogen effects, differential expression 
or activity of alcohol-metabolising enzymes, and increased sensitivity to gut derived 
endotoxins(Eagon, 2010; Sato et al., 2001). 
The pathogenesis of both NAFLD and ALD is a ‘two hit’ process. Hepatic steatosis 
constitutes the first cellular injury but a second event is required to induce 
steatohepatitis and trigger disease progression(Day, 2002; Schaffert et al., 2009). 
The second insult critically leads to oxidative stress-induced lipid peroxidation, and 
cytokine-mediated injury and inflammation. In ALD, increased plasma endotoxin 
levels correlate with disease progression and so represent part of the ‘second 
hit’(Mandrekar and Szabo, 2009). 
Acetaldehyde is a highly reactive compound produced during hepatocellular 
oxidation of ethanol by alcohol dehydrogenases(Seitz and Stickel, 2010; Setshedi et 
al., 2010)). It has a central role in ALD, with direct effects on the liver as well as 
indirect effects through increased intestinal permeability(Szabo and Bala, 2010), and 
there is increasing recognition that alcohol produced by the gut microbiome plays a 
role in NAFLD(Liu et al., 2016). Acetaldehyde is removed by oxidation to acetate by 
aldehyde dehydrogenases (ALDH). Excessive alcohol consumption leads to 
accumulation of NADH and acetyl-CoA, disrupting the metabolic balance and 
causing inhibition of fatty acid beta-oxidation and increased fatty acid synthesis(Liu, 
2014). 
ALDH2 is the Aldh isoform with the highest affinity for acetaldehyde(Marchitti et al., 
2008). Patients with an inactivating ALDH2 polymorphism(Seitz and Stickel, 2010) 
show severe responses to ethanol consumption. Aldh2 deletion in mice led to 
increased plasma acetaldehyde levels after ethanol consumption, and increased risk 
of ethanol-toxicity(Kiyoshi et al., 2009; Yu et al., 2009). These animals showed 
reduced hepatic steatosis but an enhanced inflammatory response after 4 weeks of 
ethanol treatment(Kwon et al., 2014). 
ALDH1B1 has the second highest affinity for acetaldehyde and is highly expressed 
by the intestinal epithelium and hepatocytes(Marchitti et al., 2008; Stagos et al., 
2010). We have demonstrated that Aldh1b1 depletion enhances ethanol-induced 
intestinal carcinogenesis(Müller et al., 2017) but the effect on liver damage in this 
clinically-relevant model has not been examined. We investigated the hepatic 
sequelae of Aldh1b1 loss in a mouse model of long-term ethanol consumption, using 
male and female mice to identify often overlooked sex differences. We took 
advantage of the development of late-onset obesity in C57Bl/6 mice fed a standard 
rodent diet(Becskei et al., 2009) to also model NAFLD alone or combined with 
ethanol-induced disease(Lutz and Woods, 2012). We define the sex-specific effects 
of long-term ethanol consumption and Aldh1b1-depletion in the murine liver, 
demonstrating hepatic steatosis and mild inflammation, as well as the development 
of one steatohepatitic hepatocellular carcinoma. 
Materials and Methods 
Mouse experiments 
Aldh1b1tm2a(EUCOMM)Wtsi homozygous mice (abbreviated Aldh1b1tm2a) with very low 
level residual Aldh1b1 expression in occasional intestinal crypts were analysed in a 
long-term ethanol consumption experiment as described previously(Müller et al., 
2017). Cohort sizes were chosen based on those used in previous similar work 
using. Briefly, homozygous Aldh1b1tm2a mice and wild-type littermates were 
randomised (by alternating allocation as animals of each genotype were available) to 
receive either normal drinking water or ethanol supplemented water in escalating 
doses ad libitum for one year, starting with one month of 10% (v/v) ethanol, one 
month of 15% (v/v) ethanol and 20% (v/v) ethanol for the remaining ten months. 
Ethanol supplementation started at 6-7 weeks of age, and each group consisted of 
15 animals (7-8 males and 7-8 females in each). Mice were fed a standard rodent 
maintenance diet ad libitum (RM1, Special Diets Services). All experiments were 
performed under a project licence issued under the United Kingdom Home Office 
Animals (Scientific Procedures) Act 1986. 
Immunohistochemistry and histochemistry 
Immunohistochemistry was performed as described previously(Müller et al., 2017) 
using the following primary antibodies: rabbit anti-Aldh1b1 (15560-1-AP, 
Proteintech), rabbit anti-Aldh2 (AB PB9472, Picoband), rabbit anti-Aldh1a1 
(ab52492, abcam), rabbit anti-Ki67 (ab16667, abcam), rabbit anti-Cytochrome P450 
2E1 (Cyp2e1) (ADI-100-MFO, Enzo Life Sciences) and rabbit anti-4-hydroxynonenal 
(4-HNE) (ab46545, abcam). For picrosirius red (PSR) staining, sections were 
incubated with 0.1% Sirius red F3B in saturated picric acid solution after 
pre-treatment in 0.2% phosphomolybdic acid (w/v in distilled water), and 
counterstained in 0.1% fast green FCF (w/v in acidified water). PSR stained sections 
were used for automated collagen proportionate area quantification by image 
analysis(Calvaruso et al., 2009), modified to use the application of a machine-
learning based classifier(Arganda-Carreras et al., 2017) to whole slide images after 
training in the FIJI implementation(Schindelin et al., 2012) of ImageJ(Rueden et al., 
2017). 
Immunostainings were scored based on staining intensity on blinded samples. 
Steatosis was scored on blinded samples by two pathologists using two different 
scoring systems. Pathologist 1 used the steatosis scale used in both the Non-
alcoholic Steatohepatitis Clinical Research Network (NASH CRN)(Kleiner et al., 
2005) and SAF(Bedossa et al., 2012) scoring systems for NAFLD  from 0 to 3 to 
assess quantities of large or medium sized lipid droplets (score 0:<5%, score 1: 5%-
33% [mild], score 2: 34%-66% [moderate], score 3: >67% [marked]). Pathologist 2 
used a score from 0 (no fatty change) to 4 (severe fatty change). 
Statistics 
Data were analysed with GraphPad Prism® 6 software (version 6.04), using 
unpaired, two-tailed Student’s t-test or linear regression analysis as detailed in the 
figure legends. Comparison of ordinal data generated by semi-quantitative scoring 
between treatment groups was undertaken using Mann-Whitney U-testing. 
Differences between groups were considered significant if p ≤0.05, as further 
documented in the figure legends. 
Results 
Sex-specific differences in hepatic Aldh isoform expression in normal ageing and in 
response to chronic ethanol consumption 
Protein expression of the three Aldh isoforms with highest affinity for acetaldehyde, 
Aldh2, Aldh1b1 and Aldh1a1(Marchitti et al., 2008), in the liver was quantified by 
immunohistochemistry (Figure 1). Aldh2 levels were identical in male and female 
animals. There was a significant increase in Aldh2 immunostaining intensity after 
one year of ethanol consumption in male and female Aldh1b1tm2a mice, but not in 
wild-types (Figure 1A, B).  
Aldh1b1 was only expressed in livers of wild-type mice, indicating that Aldh1b1tm2a 
mice are true knockouts in the liver. Both control and ethanol-treated female mice 
showed significantly greater hepatocellular Aldh1b1 immunostaining than male 
counterparts. Aldh1b1 levels in females were not influenced by ethanol, whereas 
significantly increased Aldh1b1 immunostaining intensity after ethanol consumption 
was observed in males (Figure 1C, D).  
In contrast, Aldh1a1 immunostaining was stronger in wild-type males than in females 
in the water-treated groups, and a significant increase after ethanol consumption 
was observed in wild-type and Aldh1b1tm2a females, but not in males (Figure 1E, F).  
There was no compensatory up-regulation of Aldh1a1 or Aldh2 in control Aldh1b1tm2a 
mice (Figure 1A, B, E, F). 
Hepatic steatosis develops spontaneously in ageing mice and is exacerbated by 
chronic ethanol consumption 
A considerable increase in body weight was observed over the 1-year treatment 
period. At the end of Week 50, the mean body weight of females in the different 
groups ranged from 30.7-33.5 g, with a maximum individual weight of 40.1 g, and the 
mean body weight of males in the different groups ranged from 32.0-40.6 g, with a 
maximum individual weight of 47.1 g (Figure S1).  
Ethanol-treated male wild-type and Aldh1b1tm2a animals had significantly lower body 
weights compared with their water-treated littermates, with a mean body weight in 
Week 50 of 32.0 g and 34.8 g in ethanol-treated wild-type and Aldh1b1tm2a males 
and a mean body weight of 38.9 g and 40.6 g in water-treated wild-type and 
Aldh1b1tm2a males, respectively. The body weights of female wild-type and 
Aldh1b1tm2a animals were unaffected by ethanol treatment (Figure S1). 
In accordance with the previously reported higher susceptibility of females to 
ethanol-induced liver damage(Iimuro et al., 1997; Wagnerberger et al., 2013), 
ethanol-treated wild-type and Aldh1b1tm2a females, but not males, displayed a 
significant increase in hepatic steatosis compared with the respective water-treated 
groups. Absolute levels of steatosis were higher in wild-type females in both ethanol 
treatment and control groups, compared with wild-type males (Figure 2, Figure S2).  
Spontaneous hepatic steatosis in the water-treated groups correlated with body 
weight, especially in males, indicating the development of NAFLD with age. A 
significant correlation of hepatic steatosis and body weight was observed in water-
treated wild-type females and water-treated Aldh1b1tm2a males (Figure 2B, H).  
Steatosis was independently scored by two experienced Pathologists using two 
different scoring systems and a statistically significant, strong correlation between 
these two sets of scores was obtained (R2=0.6457, p<0.0001) (Figure S3). 
No significant evidence that normal aging and chronic ethanol consumption induce 
steatohepatitis or fibrosis 
There was minimal necroinflammation evident in the livers of all but one animal, 
meriting their classification as simple steatosis but not steatohepatitis. In keeping 
with this, no broad scars were evident. Collagen proportionate area, derived from 
PSR-stained sections, similarly showed no significant difference between control and 
ethanol-treated animals, nor between wild-type and Aldh1b1tm2a animals, with the 
exception of a slight but significant decrease in ethanol-treated Aldh1b1tm2a males 
compared with water-treated Aldh1b1tm2a males (Figure S4). 
Ethanol treatment increases Cyp2e1 expression with evidence of lipid peroxidation 
Chronic ethanol treatment is known to increase Cyp2e1 expression(Lu and 
Cederbaum, 2008). Cyp2e1 metabolises ethanol to generate acetaldehyde, and 
reactive oxygen and nitrogen species, leading to greater lipid peroxidation. This 
mechanism has been shown to drive damage in steatohepatitis(Leclercq et al., 
2000).  
Cyp2e1 expression in water- and ethanol-treated animals showed no sex-specific 
differences although there was a trend (p=0.0598) towards greater 
Cyp2e1expression in ethanol-treated Aldh1b1tm2a males compared with respective 
females. A significant up-regulation of Cyp2e1 expression was observed in wild-type 
males and in Aldh1b1tm2a males and females (Figure 3A-E) after chronic ethanol 
exposure.  
4-HNE immunostaining was quantified as a marker of lipid peroxidation. Livers of 
water-treated females had more 4-HNE expression than water-treated males. There 
was a highly significant increase in 4-HNE immunostaining intensity in ethanol-
treated wild-type and Aldh1b1tm2a males, but not in females. After the ethanol-
induced increase in male 4-HNE expression, absolute 4-HNE expression was higher 
than in ethanol-treated females. 4-HNE expression was not affected by Aldh1b1-
depletion (Figure 3F-G).  
Increased hepatocellular proliferation induced by ethanol treatment is exacerbated 
by loss of Aldh1b1 
Untreated female animals had significantly more nuclear Ki67-immunopositive 
hepatocytes than untreated male animals. Ethanol treatment significantly increased 
the number of Ki67-immunopositive hepatocytes in wild-type females and males, and 
in Aldh1b1tm2a males (Figure 4).  
Aldh1b1tm2a males had significantly more Ki67-immunopositive hepatocytes than 
wild-type males, both in the water- and ethanol-treated groups. This is consistent 
with an exacerbation of ethanol-induced hyper-proliferation previously observed in 
the intestines of ethanol-treated Aldh1b1tm2a mice(Müller et al., 2017). 
Hepatocellular carcinoma development in an ethanol-treated Aldh1b1tm2a male 
Three large nodules of hepatocellular carcinoma were present in the liver of a single 
ethanol-treated Aldh1b1tm2a male animal (Figure 5A). Microscopically, nodules 
lacked portal tracts but contained unaccompanied arterial branches, and the normal 
sinusoidal structure was absent (Figure 5B). Lesional cells demonstrated nuclear 
enlargement and pleomorphism, with variable cellular ballooning, small Mallory-Denk 
bodies and steatosis (Figure 5C), meriting classification as steatohepatitic 
HCC(Salomao et al., 2012). Intralesional fibrosis was prominent (Figure 5D). 
Discussion 
Fatty liver disease represents a significant health burden; alcoholic liver disease is 
the largest single primary aetiology requiring liver transplantation in the UK(NHS 
Blood and Transplant, 2016), whilst in four European countries (Germany, France, 
Italy, and UK) there are an estimated 52 million people with NAFLD at an annual 
cost of €35 billion(Younossi et al., 2016).  
Women have a greater risk of chronic damage in alcoholic liver disease. In 
accordance with this, hepatic steatosis after long-term ethanol-treatment was only 
observed in females in this study, and ethanol induced more hepatic 
hyperproliferation in wild-type females than in males. The putative mechanisms 
behind this are unclear but may include the effects of oestrogen, differential 
expression or activity of alcohol-metabolising enzymes, and increased sensitivity to 
gut derived endotoxins(Eagon, 2010; Sato et al., 2001). The incidence of non-
alcoholic fatty liver disease in lean individuals is also higher in females(Younossi et 
al., 2012), and there is also twice the rate of non-alcoholic steatohepatitis, predicting 
fibrosis progression, in female NAFLD patients(Neuschwander-Tetri et al., 2010). 
We have shown complex sex-specific differences in the Aldh enzymes responsible 
for metabolising acetaldehyde in response to both ageing and alcohol. In a recent 
mass spectrometry-based proteomics approach, the two Aldh isoforms with the 
highest affinity for acetaldehyde, Aldh2 and Aldh1b1, were up-regulated after 
ethanol-consumption in male, but not in female mouse livers(Wang et al., 2014). In 
agreement with this, we detected increased Aldh1b1 immunostaining intensity after 
one year of ethanol consumption in male but not in female wild-type and Aldh1b1tm2a 
mice in this study. Interestingly, our data show that Aldh1b1 immunostaining intensity 
in females was not responsive to ethanol consumption, but was significantly stronger 
than in males in both water- and ethanol-treated wild-type females. 
Animals were examined at an advanced age more in keeping with the development 
of NAFLD in humans than is often used in rodent modelling of chronic liver disease. 
Steatosis was present in the livers of some male and female control animals; in 
female wild-type animals there was a correlation between extent of steatosis and 
body weight. This indicates the spontaneous development of NAFLD in ageing 
C57/Bl6 mice, and indicates that disease in ethanol-treated animals represents the 
additive effect of both aetiologies. 
We have previously observed a nearly twofold increase in plasma acetaldehyde 
levels in ethanol-treated Aldh1b1tm2a mice compared with ethanol-treated wild-type 
littermates(Müller et al., 2017). Acetaldehyde is critically involved in the development 
of ALD, and ALDHs have a crucial role in protecting from ethanol-induced liver 
damage. Ethanol consumption led to increased plasma and liver acetaldehyde levels 
in a mouse model, along with steatosis, inflammation and an increase in liver 4-HNE 
levels, which was alleviated by co-administration of an ALDH activator(Zhong et al., 
2015).  
In Aldh1b1tm2a mice lacking hepatic Aldh1b1, the only compensatory change was 
increased Aldh2 expression after chronic ethanol exposure, which was not observed 
in wild-type littermates. Increased 4-HNE levels, reflecting lipid peroxidation, after 
ethanol treatment were demonstrated, as expected(Zhong et al., 2015), in male wild-
type and Aldh1b1tm2a mice. Increased Cyp2e1 immunostaining, an important 
contributor to hepatic oxidative stress after ethanol-consumption(Lu and Cederbaum, 
2008), was confirmed in ethanol-treated wild-type and Aldh1b1tm2a males as well as 
in Aldh1b1tm2a females. However, there was no significant difference in 4-HNE or 
Cyp2e1 between genotypes, nor differences in the steatotic response to chronic 
ethanol exposure. 
These data demonstrate that compensatory hepatic over-expression of Aldh2 is 
sufficient to reduce potential increases in plasma acetaldehyde and prevent 
increased liver damage and is an example of inherent, protective, biological 
redundancy. This also suggests profound functional differences between Aldh2 and 
Aldh1b1. In contrast to Aldh1b1 loss, Aldh2 deletion in mice aggravated alcohol-
induced hepatic oxidative stress and inflammation, but ameliorated steatosis and 
hepatocellular injury after 4 weeks of ethanol consumption(Kinoshita et al., 2008; 
Stagos et al., 2010). Steatosis after ethanol consumption is caused by accumulation 
of NADH and acetyl-CoA that results in inhibition of fatty acid beta-oxidation and 
increased fatty acid synthesis. Depletion of Aldh2 causes a more than tenfold 
increase of plasma acetaldehyde in ethanol-treated Aldh2 knockout mice compared 
with wild-types(Kiyoshi et al., 2009), compared with a twofold increase in Aldh1b1-
depleted mice(Müller et al., 2017; Singh et al., 2015). 
Increased hepatic proliferation after ethanol consumption has been previously 
reported(Baroni et al., 1994; Chung et al., 2001). In our study, this response was 
greater in wild-type females than in males. Aldh1b1-depletion exacerbated ethanol-
induced hyperproliferation in males, although absolute proliferation rates remained 
higher in female animals for each condition. Development of steatohepatitic HCC is 
associated with ALD and NAFLD(Salomao et al., 2012), including in non-cirrhotic 
liver(Baffy et al., 2012). Steatohepatitic HCC developed in the only animal showing 
background steatohepatitis, in an ethanol-treated, Aldh1b1-depleted male. Together, 
these data suggest that Aldh1b1, particularly in males, plays a protective role from 
ethanol-induced hepatocellular proliferation. As only a single ethanol-treated, 
Aldh1b1 depleted male developed HCC, definitive conclusions are precluded, but the 
male sex and genotype are intriguing and a longer ethanol treatment study of 
Aldh1b1 knockout mice is warranted to further study the protective role of Aldh1b1 in 
the liver. 
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